Allostery Investments LP Sells 20,798 Shares of KalVista Pharmaceuticals, Inc. $KALV

Key Points

• Allostery Investments LP reduced its stake in KalVista Pharmaceuticals by 4.3%, now holding 458,302 shares worth approximately $5.3 million.
• Several other institutional investors, including Rhumbline Advisers and Corebridge Financial, have also increased their positions in KalVista Pharmaceuticals during the first quarter.
• KalVista Pharmaceuticals reported a significant earnings miss of ($3.69) EPS, which was below analyst expectations of ($0.83).

Allostery Investments LP lessened its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 4.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 458,302 shares of the specialty pharmaceutical company's stock after selling 20,798 shares during the period. KalVista Pharmaceuticals accounts for approximately 7.6% of Allostery Investments LP's portfolio, making the stock its 3rd largest position. Allostery Investments LP owned approximately 0.92% of KalVista Pharmaceuticals worth $5,289,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Earned Wealth Advisors LLC acquired a new position in KalVista Pharmaceuticals in the first quarter valued at $44,000. GAMMA Investing LLC raised its holdings in shares of KalVista Pharmaceuticals by 567.3% in the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock valued at $51,000 after buying an additional 3,767 shares during the last quarter. CWM LLC raised its holdings in shares of KalVista Pharmaceuticals by 12,636.1% in the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company's stock valued at $53,000 after buying an additional 4,549 shares during the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $44,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after buying an additional 5,502 shares during the last quarter.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 32,979 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total value of $517,440.51. Following the completion of the transaction, the chief executive officer directly owned 369,595 shares of the company's stock, valued at approximately $5,798,945.55. This trade represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 2,942 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.22, for a total transaction of $38,893.24. Following the completion of the transaction, the insider directly owned 119,841 shares of the company's stock, valued at approximately $1,584,298.02. This trade represents a 2.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 59,710 shares of company stock valued at $880,764. 4.30% of the stock is currently owned by corporate insiders.

KalVista Pharmaceuticals Stock Up 4.1%

NASDAQ KALV traded up $0.62 during trading hours on Friday, hitting $15.82. 1,079,460 shares of the stock were exchanged, compared to its average volume of 680,137. The company has a market cap of $796.38 million, a price-to-earnings ratio of -4.29 and a beta of -0.10. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $16.32. The stock has a 50-day moving average of $13.79 and a 200 day moving average of $12.64.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same period in the previous year, the firm earned ($1.07) EPS. On average, equities research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on KALV. Leerink Partners upped their target price on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a report on Monday, July 7th. HC Wainwright upped their target price on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Finally, JMP Securities upped their target price on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $26.29.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).